![Eli Wilner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Eli Wilner
Director Ejecutivo en Eli Wilner & Co. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Owen M. Lopez | M | 83 |
National Museum of American Art of the Smithsonian
![]() National Museum of American Art of the Smithsonian Other Consumer ServicesConsumer Services The National Museum of American Art of the Smithsonian operates a museum and is ultimately controlled by the Government of the United States of America. The company is based in Washington. | - |
Frederick David Hill | M | - |
National Museum of American Art of the Smithsonian
![]() National Museum of American Art of the Smithsonian Other Consumer ServicesConsumer Services The National Museum of American Art of the Smithsonian operates a museum and is ultimately controlled by the Government of the United States of America. The company is based in Washington. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Shalom Hirschman | M | 85 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Stephen M. Elliston | M | 73 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Barry Kaplan | M | - |
Brandeis University
| 4 años |
Jerome Kemp | M | - |
Brandeis University
| 4 años |
Eric Weinstein | M | 71 |
Brandeis University
| 4 años |
Ralph C. Martin | M | - |
Brandeis University
| 4 años |
Andrew B. Hahn | M | - |
Brandeis University
| 3 años |
Michael J. Gresser | M | - |
Brandeis University
| 3 años |
Michael N. Kahn | M | - |
Brandeis University
| 4 años |
Fernando Torres-Gil | M | - |
Brandeis University
| 3 años |
Dan Jick | M | - |
Brandeis University
| 4 años |
Richard M. Blau | M | - |
Brandeis University
| 4 años |
Brad Bederman | M | - |
Brandeis University
| 4 años |
David Segal | M | 68 |
Brandeis University
| 4 años |
Daniel I. Schlessinger | M | - |
Brandeis University
| 4 años |
Andy R. Stern | M | - |
Brandeis University
| 4 años |
Stanley Roth | M | - |
Brandeis University
| 4 años |
Charalampos A. Makkas | M | 72 |
Brandeis University
| 4 años |
Larry H. Levy | M | - |
Brandeis University
| 4 años |
Richard Alexander | M | - |
Brandeis University
| 4 años |
Windsor N. Hall | M | - |
Brandeis University
| 4 años |
Adam Henick | M | - |
Hunter College
| 2 años |
Daniel J. Jick | M | - |
Brandeis University
| 4 años |
Karen M. Muller | F | 69 |
Hunter College
| 4 años |
William D. Freedman | M | - |
Brandeis University
| 4 años |
Christie Hefner | F | 71 |
Brandeis University
| 4 años |
Perry Traquina | M | 68 |
Brandeis University
| 4 años |
Jacqueline Sonnabend | F | 69 |
Brandeis University
| 4 años |
Richard Northern | M | 75 |
Brandeis University
| 3 años |
Bill Wittenberg | M | - |
Brandeis University
| 4 años |
Eric Cohen | M | 66 |
Brandeis University
| 4 años |
Elma Hawkins | M | 67 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
David A. Kadish | M | 71 |
Brandeis University
| 1 años |
Richard Seth Rosen | M | 66 |
Brandeis University
| 4 años |
Charles H. Moore | M | 94 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Curt S. Rush | M | 70 |
Hunter College
| 4 años |
David Seligman | M | - |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 4 años |
Nancy J. van Sant | F | - |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 4 años |
Roy S. Walzer | M | 76 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 7 años |
Irach Taraporewala | M | 68 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 6 años |
Candace E. Browning-Platt | F | - |
Brandeis University
| 4 años |
Gilbert L. Drozdow | M | - |
Brandeis University
| 4 años |
William J. Kane | M | - |
Brandeis University
| 4 años |
Joshua Ostroff | M | - |
Brandeis University
| 4 años |
Angelo S. Botter | M | 76 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 3 años |
Wendee Wolfson | F | - |
Brandeis University
| 4 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 48 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Eli Wilner
- Red Personal